Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Placing

3 Aug 2018 08:00

RNS Number : 7486W
FastForward Innovations Limited
03 August 2018
Β 

For Immediate Release

3 August 2018

FastForward Innovations Limited

("FastForward" or the "Company")

Β 

Placing

Director Dealing

Β 

Further to the announcement by FastForward Innovations Limited (AIM: FFWD) on 1 August 2018, the Company is pleased to announce that it has today agreed to place 30,769,230 newΒ Ordinary Shares of 1p eachΒ (the "Placing Shares")Β at a price of 13p per Placing ShareΒ with a number of new and existing investors thereby raising gross proceeds of Β£4,000,000 (US$5,240,000 at an exchange rate of Β£1:US$1.31, being the rate on the date the Company determined the terms of the placing) before expenses (the "Placing"). The Placing Price represents a premium of approximately 27.7% to the Company's most recently published NAV per share of 10.18p. The Placing is being done by way of a placing through the Company's brokers and a direct subscription by the Company (together the "Placing"). The net proceeds of the Placing will be used to repay the Director's Loan announced on 23 July 2018, assist the Company in making investments in accordance with its investing policy and for general working capital purposes.

Β 

Subject to payment, application for the Placing Shares (which will rankΒ pari passuΒ with the existing Ordinary Shares) to be admitted to trading on AIM ("Admission") will be made with dealings expected to commence at 8.00 a.m. on 10 August 2018.

Β 

The Company expects that the enlarged issued share capital following the issue of the Placing Shares will be 166,913,727 Ordinary Shares (the "Enlarged Issued Share Capital").

Β 

The Company is reviewing its options to allow Shareholders the ability to subscribe for new Ordinary Shares on the same terms as the Placing and expects to update investors on this shortly.

Β 

Commenting on the Placing, Chief Executive Officer Lorne Abony noted:

Β 

"The placing funds allow the Company to take advantage of potential opportunities for new and follow on investments. I am pleased to see the support the Board and existing significant Shareholders have provided and see this as a vote of confidence in what we are building.

Β 

It is disappointing that the share price did not pick up after the recent newsflow, and that this round of funding is at 13p. For this reason the Board is committed to providing an opportunity for existing shareholders to also participate on the same terms. The intention had been to complete the Placing at a higher price but the share price did not react as expected after the Vogogo, Leap, Intensity and Factom investments, which the Board maintain are excellent investment opportunities. Similarly, whilst the pricing of the deal was disappointing for all concerned, the Company thanks investors for their support and will continue to pursue best in class investment opportunities inline with its investing policy, including within the Blockchain, Medical Cannabis and Artificial Intelligence sectors which the board believes offers the highest growth potential at present."

Β 

Β 

Related Party Transaction

Β 

Mr Lorne Abony and Mr Jim Mellon (who are each Directors of the Company) have participated in the Placing. The participation of the Directors is as set out below:

Β 

Name

Subscription

Placing Shares

Total Ordinary Shares (inc. Placing Shares)

Β 

% interest in the Enlarged Issued Share Capital (excluding those shares held in Treasury)

Lorne Abony1

Β£487,000

3,746,154

15,994,588

9.90%

Jim Mellon2

Β£761,505

5,857,731

16,283,722

10.08%

1Β Lorne Abony's interest in shares is held by Abony Enterprises Limited Partnership, a limited partnership of which he is the majority legal owner.

2Β Mr Mellon's interest in the Company's shares is held by Galloway Limited, a company owned by a trust of which Mr James Mellon is a life tenant, in respect of 10,425,991 shares and directly by Mr Mellon in respect of 5,857,731 shares.

Β 

The Directors are related parties for the purposes of the AIM Rules. The participation of the two Directors in the Placing constitutes a Related Party Transaction under Rule 13 of the AIM Rules for Companies.

Β 

Accordingly, Mr Ian Burns, the Company's Finance Director (Mr Edward McDermott, Non-Executive Director, is an employee of the Company's Brokers, Optiva Securities Limited, and so is not regarded as independent for the purposes of the Placing), is the independent director of the Company for the purposes of the Placing. Mr Ian Burns confirms that, having consulted with the Company's Nominated Adviser, the terms of the Placing are fair and reasonable insofar as the Company's shareholders are concerned. In particular Mr Burns notes that the Directors have participated on the same terms as all other placees.

Β 

The Investors

Β 

In addition to Mr Abony and Mr Mellon, following the issue of the Placing Shares the following shareholder will be interested in more than 3 per cent. of the Enlarged Issued Share Capital (excluding those shares held in Treasury):

Β 

Name

Subscription

Placing Shares

Total Ordinary Shares (inc. Placing Shares)

Β 

% interest in the Enlarged Issued Share Capital (excluding those shares held in Treasury)

LOM Nominees

Β£761,505

5,857,731

5,857,731

3.63%

Β 

Β 

Issued Shares

Β 

Following Admission of the Placing Shares, the Company's issued share capital consists of 166,913,727Ordinary Shares. 5,413,623 Ordinary shares are held in Treasury. For reporting under the FCA's Disclosure and Transparency Rules, Shareholders should exclude any shares held in Treasury and should use the figure of 161,500,104 Ordinary Shares (the issued voting share capital) when determining if they are required to notify their interest, or a change of their interest in the Company.

Β 

The Market Abuse Regulation ("MAR") became effective from 3 July 2016. Market soundings, as defined in MAR, were taken in respect of the Fundraise with the result that certain persons became aware of inside information, as permitted by MAR. That inside information is set out in this announcement and has been disclosed as soon as possible in accordance with paragraph 7 of article 17 of MAR. Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

Β 

Β 

For further information on the Company please visitΒ www.fstfwd.coΒ or contact:

FastForward Innovations Limited

info@fstfwd.co

Sue Saunders / Ian Burns

Β 

Beaumont Cornish Limited (Nomad)

James Biddle / Roland Cornish

Tel: +44 207 628 3396

Β 

Optiva Securities Limited (Broker)

Graham Dickson Tel: +44 (0) 203 137 1902

Β 

Β 

Β 

DISCLAIMER

Β 

Beaumont Cornish Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as Nominated adviser to FastForward Innovations Limited and no one else in connection with the Placing and will not be responsible to anyone other than FastForward Innovations Limited for providing the protections afforded to clients of Beaumont Cornish Limited nor for providing advice in relation to the Placing. Neither Beaumont Cornish Limited nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Beaumont Cornish Limited in connection with this Announcement, any statement contained herein, or otherwise.

Β 

CAUTIONARY STATEMENT

Β 

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives ofΒ FastForward Innovations Limited. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice.Β FastForward Innovations Limited assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
IOEGLGDISUGBGIX
Date   Source Headline
25th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
18th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
11th Feb 20207:00 amRNSUpdated Key Information Document
31st Jan 20201:30 pmRNSInvestee Company Update: Portage Biotech Inc.
8th Jan 20207:00 amRNSDisposal of Interest in Cryptologic Corp
7th Jan 20207:00 amRNSBoard Appointment
3rd Jan 20201:15 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Dec 20197:00 amRNSHalf-year Report
5th Dec 20192:45 pmRNSTR-1 Notification
19th Nov 20197:00 amRNSLorne Abony appointed as Chairman of EMMAC
16th Oct 20197:00 amRNSInvestee Company Update: EMMAC Life Sciences
15th Oct 20197:00 amRNSInvestee Company Update: Factom inc.
10th Oct 20199:25 amRNSResult of 2019 AGM
27th Sep 20194:31 pmRNSDirector Dealing in the Company
27th Sep 20197:00 amRNSInvestee Company Update : Fralis LLC (Leap Gaming)
26th Sep 201911:21 amRNSInvestee Company Update : Cryptologic Corp
16th Sep 201911:52 amRNSTR-1 Notification of major holdings
11th Sep 20198:00 amRNSResults for the year ended 31st March 2019
11th Sep 20198:00 amRNSNotice of 2019 Annual General Meeting
22nd Aug 201912:01 pmRNSDirectorate Change
19th Aug 20199:23 amRNSJuvenescence closes Series B funding
12th Aug 20193:02 pmRNSInvestee Company Update-Cryptologic issues loan
12th Aug 201910:11 amRNSPortage Trading Suspended
6th Aug 20194:42 pmRNSInvestee Company Update: Cryptologic Corp
30th Jul 201911:07 amRNSSAFE Agreement with Factom, Inc. Extended
25th Jul 20198:17 amRNSFactom Inc SAFE Agreement temporary extension
18th Jul 201911:20 amRNSInvestee Company Update: Regent Pacific on Yooya
16th Jul 20199:13 amRNSInvestee Company Update:EMMAC acquires Terre Verde
11th Jul 20193:00 pmRNSDisposal of interest in Intensity Therapeutics Inc
9th Jul 201910:51 amRNSInvestee Company Update: EMMAC enters new Market
26th Jun 20198:56 amRNSInvestee Company Update: Intensity Therapeutics
29th May 20193:43 pmRNSInvestee Company Update: Offer for Yooya
13th May 201910:21 amRNSDisposal of interest in Vemo Education Inc.
18th Apr 20197:00 amRNSInvestee Company Update: Intensity Therapeutics
4th Apr 20199:51 amRNSTR1 - Correction
3rd Apr 20194:00 pmRNSTR:1 Regent Mercantile Holdings Limited
20th Mar 201911:00 amRNSCompletion of £2 million investment in EMMAC
7th Mar 20194:03 pmRNS£2 million investment in EMMAC Life Sciences
15th Jan 20193:45 pmRNSJuvenescence Series B Funding
3rd Jan 201911:47 amRNSBoard Appointment
12th Dec 201812:52 pmRNSHalf-year Report
3rd Dec 20187:00 amRNSInvestee Company Update: Factom and Yooya
14th Nov 20181:31 pmRNSInvestee Company Update: Factom Inc
22nd Oct 201812:24 pmRNSIntensity Therapeutics Inc Update
12th Sep 20186:12 pmRNSResult of AGM
10th Sep 20189:16 amRNSHolding(s) in Company
22nd Aug 20188:08 amRNSDirector Dealing
3rd Aug 201812:48 pmRNSShareholder update
3rd Aug 20188:00 amRNSPlacing
1st Aug 201812:05 pmRNSResponse to Media Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.